Microdosing GLP-1 medications — taking semaglutide or tirzepatide below the doses the FDA-approved labels aim for — is one of the fastest-spreading ideas in weight loss right now. The promise sounds great: less nausea, a smaller bill, just enough appetite control. Here is the sentence every honest guide has to lead with: no major randomized trial has tested microdosing for weight loss. The famous results — about 14.9% average weight loss over 68 weeks in the STEP 1 trial and up to ~20.9% over 72 weeks in SURMOUNT-1 — all came from full therapeutic doses. This guide covers what the evidence actually shows, where the real risks sit, and the narrow cases where a lower dose genuinely makes clinical sense.
What Microdosing GLP-1 Actually Means
The FDA-approved dosing schedules treat low doses as a ramp, not a destination. Per the Wegovy prescribing information, semaglutide starts at 0.25 mg once weekly — described in the label as a starting dose for treatment initiation, not a treatment dose — and climbs every 4 weeks to a 2.4 mg maintenance dose at week 17. Zepbound (tirzepatide) starts at 2.5 mg weekly and climbs toward a 15 mg maximum.
Microdosing flips that logic. Instead of climbing the ladder, you deliberately stay near the bottom — holding semaglutide at 0.25 or 0.5 mg, or tirzepatide at its 2.5 mg starter step — indefinitely. Our semaglutide dosage chart shows the full standard schedule for comparison.
| Approach | Typical weekly dose | Evidence behind it |
|---|---|---|
| FDA-approved Wegovy schedule | 0.25 mg ramping to 2.4 mg over ~16 weeks | STEP 1 randomized trial: ~14.9% average loss at 68 weeks |
| FDA-approved Zepbound schedule | 2.5 mg ramping up to 15 mg | SURMOUNT-1 randomized trial: up to ~20.9% at 72 weeks |
| Microdosing | Holding at the lowest steps long term | No major randomized trial |
Two more facts define the practice. It is off-label — legal for a licensed clinician to prescribe, but outside anything the FDA has evaluated. And it almost always runs on compounded vials, because brand-name pens come in fixed doses you cannot split. Compounded semaglutide and tirzepatide are not FDA-approved, a distinction the FDA itself stresses in its guidance on unapproved GLP-1 drugs.
What the Trials Actually Tested — and What They Didn’t
The evidence base for GLP-1 weight loss is strong, but it is strong at specific doses. In the STEP 1 trial, adults injecting 2.4 mg semaglutide weekly alongside diet and exercise lost an average of 14.9% of body weight over 68 weeks. In SURMOUNT-1, tirzepatide produced roughly 15% average loss at the 5 mg dose and up to ~20.9% at 15 mg over 72 weeks.
Notice two things in those numbers. First, even the lowest dose SURMOUNT-1 tested — 5 mg of tirzepatide — is a full therapeutic dose, double the 2.5 mg starter step. Second, within the trial, lower doses produced less weight loss. The dose-response curve points in exactly the direction microdosing hopes it doesn’t.
Below the labeled starting doses, the published record is essentially empty. What supports microdosing today is a mix of clinician experience, patient anecdotes, and provider marketing — one telehealth company advertises average low-dose results in company materials, but that is marketing, not a peer-reviewed trial. When someone tells you microdosing “works,” ask which randomized study they mean. There isn’t one.
Why People Do It Anyway: The Two Real Drivers
Microdosing is not spreading because of new science. It is spreading because of cost and side effects — and both motivations are understandable.
The cost math is blunt. Brand-name Wegovy runs about $1,300+ per month at retail without insurance, and even compounded standard-dose plans cost roughly $99–$349/month through telehealth, per the pricing we track. A smaller dose sounds like a smaller bill, and low-dose plans are marketed from $79 for a first month.
The side-effect math is real too. Per the Mayo Clinic, the most common semaglutide side effects — nausea, vomiting, diarrhea, and constipation — tend to cluster after dose increases, and they generally scale with dose. Per the Cleveland Clinic, GLP-1 agonists slow stomach emptying, which is exactly why higher doses hit the gut harder. People who felt wrecked at 1 mg reasonably wonder whether 0.5 mg could deliver some benefit without the misery.
There is a third, quieter driver: marketing to people who never qualified for these drugs. Some low-dose programs have reportedly loosened entry criteria well below the BMI 30+ (or 27+ with a weight-related condition) standard that the approved labels and most telehealth providers use. Lower doses sold to lower-BMI customers expands the market — it does not expand the evidence.
Microdosing GLP-1 Risks the Ads Skip
Risk one: paying for nothing. These drugs have a dose floor somewhere — the Wegovy label calls 0.25 mg a starting dose precisely because it is not expected to deliver the treatment effect. If your microdose sits below your personal threshold, you are spending $199 a month for appetite suppression that never arrives, while telling yourself the subscription is an investment.
Risk two: measurement errors get worse at small doses. The FDA has received reports of dosing errors with compounded GLP-1s, including patients who drew the wrong volume from multi-dose vials and injected multiple times their intended dose, some needing medical attention. Small doses magnify the problem: at a common 2.5 mg/mL concentration, 0.25 mg is just 10 units on an insulin syringe — so a draw that is off by 5 units is a 50% dosing error. The tinier the target, the bigger every wobble.
Risk three: the product itself. Microdosing runs on compounded medication, and compounded semaglutide and tirzepatide are not FDA-approved — the agency does not verify their safety, quality, or potency before sale, as its compounding Q&A explains. You are stacking an untested dosing strategy on top of an unapproved product.
Risk four: no long-term data. Nobody knows what years of sub-therapeutic GLP-1 exposure does — for benefit or harm — because it has not been studied. That is not automatically dangerous. It is automatically unknown, and unknown is not what the ads are selling.
When Clinicians Legitimately Use Lower Doses
None of the above means low doses are always a gimmick. There are real, defensible uses — the difference is that a clinician sets them for a reason.
Slowing the ramp is built into the label. The Wegovy prescribing information allows delaying each escalation by 4 weeks if a dose is not tolerated, and permits dropping from 2.4 mg back to 1.7 mg for up to 4 weeks. Taking 20+ weeks to reach maintenance is normal medicine, not microdosing.
Lowest effective dose is a real principle. Some patients get meaningful appetite control below 2.4 mg, and a clinician who holds a patient at 1 mg because it is working is practicing judgment, not chasing a trend. The label’s maintenance target is a population number; your response is individual.
Maintenance after weight loss is the most interesting case. Stopping GLP-1s entirely usually leads to significant regain, as our guide to what happens when you stop GLP-1s explains. Some clinicians therefore keep patients on a reduced dose after goal weight instead of quitting cold. That is still off-label with no long-term trial behind it — but it is a supervised strategy aimed at a documented problem, which is very different from a $79 impulse subscription.
The common thread: in every legitimate case, a licensed prescriber chooses the dose, monitors the result, and adjusts. If your dose was set by a website, a TikTok protocol, or your own math on a vial, you are not in this category.
What a Low-Dose Plan Costs in 2026
Here is the trap nobody expects: microdosing can cost more per milligram — and sometimes more per month — than full-dose treatment. Prices below were verified in July 2026.
| Option | What you pay | The catch |
|---|---|---|
| Named microdose tier (Noom Med) | $79 first month, then $199/mo billed quarterly | Settles higher than some full-dose plans |
| Flat-price compounded plans | ~$99–$349/mo, same price at every dose | Low dose costs the same as full dose |
| Brand-name Wegovy, cash retail | ~$1,300+/mo | Fixed-dose pens make microdosing impractical |
Run the comparison before you buy. Several telehealth companies sell standard-dose compounded semaglutide for $99–$129 per month on plan pricing — less than the $199/month a dedicated microdose tier settles at after its promo. Our comparison of GLP-1 microdosing providers breaks down which programs let a clinician hold a low dose without a price penalty, and our ranking of the cheapest online GLP-1 providers shows what full-dose treatment costs, so you can see both sides of the math.
And never stretch doses yourself to save money — splitting or skipping prescribed doses from a vial is exactly the self-directed dosing the FDA’s warnings about compounded GLP-1s describe.
Questions to Ask Before You Try It
If you are still considering a low-dose plan, take four questions to a licensed clinician — not to a checkout page.
What dose, and why that dose? A real answer references your history and a plan, not a subscription tier. What result would count as working? Agree on a number — appetite, weight, or both — before you start paying. When do we reassess? Eight to twelve weeks is a reasonable checkpoint; an open-ended low-dose subscription with no review date mostly benefits the biller. What is the exit plan? Titrating up to evidence-backed doses if the microdose does nothing, or stopping entirely, should be decided in advance.
Microdosing GLP-1 therapy is not a scam, and it is not a breakthrough. It is an unproven, off-label practice with plausible logic, real risks, and heavy marketing — worth discussing with a clinician, and worth zero dollars of your money on autopilot.